Prevention by intrarectal 5-aminosalicylic acid of n-methylnitrosourea-induced colon cancer in f344 rats

Diseases of the Colon and Rectum

Volumn 46, Issue 7, 2003, Pages 900-903

  Narisawa, Tomio ^a   Fukaura, Yoko ^a  

^a NONE

Author keywords

5 Aminosalicylic acid; Chemoprevention; Colon cancer

Indexed keywords

MESALAZINE; METHYLNITROSOUREA; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; COLON; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; NONHUMAN; RAT; RAT STRAIN;

ADMINISTRATION, RECTAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; FEMALE; MESALAMINE; METHYLNITROSOUREA; RATS; RATS, INBRED F344;

EID: 0038115225     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10350-004-6681-3     Document Type: Article

References (15)

1. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998;90:1609-20.
2. Little J. Aspirin and other nonsteroidal antiinflammatory drugs and colorectal neoplasia. Int J Oncol 1994;5:1151-62.
3. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7.
4. Hirata K, Itoh H, Ohsato K. Regression of rectal polyps by indomethacin suppository in familial adenomatous polyposis: report of two cases. Dis Colon Rectum 1994;37:943-6.
5. Hirota C, Iida M, Aoyagi K, et al. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer 1996;78:1660-5.
6. Hordijk ML, Shivananda S. Risk of cancer in inflammatory bowel disease: why are the results in the reviewed literature so varied? Scand J Gastroenterol 1989;24(Suppl 170):70-4.
7. Ekbom A, Helmick C, Zeck M, Adami HO. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med 1990;323:1228-33.
8. Pinczowski D, Ekbom A, Baron J, Yuen J. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107:117-20.
9. Narisawa T, Sato T, Hayakawa M, Sakuma A, Nakano H. Carcinoma of the colon and rectum of rats by rectal infusion of N-methyl-N′-nitro-N-nitrosoguanidine. Jpn J Cancer Res 1971;62:231-4.
10. Narisawa T, Fukaura Y, Takeba N, Nakai K. Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats. Jpn J Cancer Res 2002;93:143-50.
11. Rijk MC, Van Schaik A, Van Togeren JH. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Scand J Gastroenterol 1988;23:107-12.
12. Davis AE, Patterson F, Crouch R. The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. Br J Cancer 1992;66:777-80.
13. Kennedy M, Wilson L, Szabo C, Salzman AL. 5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med 1999;4:437-43.
14. Craven PA, Pfanstiel J, Saito R, DeRubertis FR. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cells and proliferative activity. Gastroenterology 1987;92:1998-2008.
15. Bus PJ, Nagtegaal ID, Verspaget HW, et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 1999;13:1397-402.